Prostate Cancer Metastatic Castration-Resistant (mCRPC)

What Metastatic Castration-Resistant (mCRPC) Means

Metastatic disease with rising PSA despite castrate testosterone (<50 ng/dL)

Treatment Approach for Metastatic Castration-Resistant (mCRPC)

Sequence of hormone therapies (abiraterone, enzalutamide, apalutamide) or chemotherapy (docetaxel, cabazitaxel). Lu-177 PSMA if PSMA-positive and progressed through hormonal therapy. Median survival 2–3 years with optimal sequencing.

Survival Rates and Prognosis

The 5-year survival rate for prostate cancer at Metastatic Castration-Resistant (mCRPC) is approximately 15%–30% (10-yr: <10%). Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Very Low Risk	99%+ (10-yr: 98%+)	Active surveillance preferred. Annual PSA, DRE, repeat biopsy in 1–2…
Low Risk	98%+ (10-yr: 95%)	Active surveillance or definitive therapy (RARP or radiation). Discuss 10-year…
Intermediate Risk	95% (10-yr: 88%–92%)	Definitive therapy: RARP with or without pelvic lymph node dissection, or EBRT…
High Risk	88%–93% (10-yr: 75%–85%)	Definitive therapy + ADT. EBRT – 24–36 months ADT preferred if fit….
Very High Risk	70%–85% (10-yr: 55%–75%)	Aggressive systemic therapy. EBRT – 36+ months ADT with or without…
Metastatic Hormone-Sensitive (mHSPC)	40%–60% (10-yr: 10%–25%)	Upfront ADT + docetaxel (STAMPEDE/CHAARTED trials showed docetaxel improves…